Compare PulteGroup, Inc. (PHM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs ResMed Inc. — how do they compare? PulteGroup, Inc. trades at $113.37 (market cap $21.40B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and ResMed Inc. for 51 Days on average.
| PHM | RMD | |
|---|---|---|
Market Cap | $21.40B | $31.78B |
Volume | 2,220,826 | 1,128,382 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $277.88 |
52-Week Low | $110.11 | $182.82 |
Typical Hold Time | 91 Days | 51 Days |
Enterprise Value | $21.81B | $31.14B |
Dividend Yield | 0.93% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $113.53, down 2.22% amid broader market weakness. The stock shows bearish technical signals with RSI at oversold levels near 19.42, while fundamentals remain solid with a P/E of 11.47 and strong profitability metrics including 14.9% ROE. Recent earnings show mixed results with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing estimates. The company maintains positive cash flow generation with $355.10M net cash flow in 2025.
PHM presents a value opportunity with attractive valuation multiples, though facing headwinds from rising mortgage rates impacting the housing sector. Analyst consensus targets $139.80 (23% upside) with 45% buy ratings, but technical indicators suggest near-term pressure. Key risks include housing market sensitivity to interest rates and margin compression from recent earnings misses.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
